Mesoblast (MESO)

$6.27

+0.05

(+0.8%)▲

Live

Insights on Mesoblast

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.13M → 1.69M (in $), with an average decrease of 20.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -21.91M → -16.26M (in $), with an average increase of 34.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 57.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 303.1%

Performance

  • $5.90
    $6.27
    $6.27
    downward going graph

    5.85%

    Downside

    Day's Volatility :5.85%

    Upside

    0.0%

    downward going graph
  • $1.61
    $40.96
    $6.27
    downward going graph

    74.32%

    Downside

    52 Weeks Volatility :96.07%

    Upside

    84.69%

    downward going graph

Returns

PeriodMesoblastSector (Health Care)Index (Russel 2000)
3 Months
247.49%
1.7%
0.0%
6 Months
-36.79%
11.3%
0.0%
1 Year
1.97%
5.4%
1.3%
3 Years
-61.7%
13.9%
-22.1%

Highlights

Market Capitalization
677.5M
Book Value
$0.5
Earnings Per Share (EPS)
-0.87
PEG Ratio
0.0
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
-784.65%
Return On Assets TTM
-5.61%
Return On Equity TTM
-14.49%
Revenue TTM
7.5M
Revenue Per Share TTM
0.09
Quarterly Revenue Growth YOY
-11.700000000000001%
Gross Profit TTM
-47.4M
EBITDA
-57.9M
Diluted Eps TTM
-0.87
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.72
EPS Estimate Next Year
-0.78
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    66%Buy
    22%Hold
    11%Sell
Based on 9 Wall street analysts offering stock ratings for Mesoblast(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
8
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 27.59%

Current $6.27
Target $8.00

Company Financials

FY18Y/Y Change
Revenue
17.3M
↑ 618.95%
Net Income
-35.3M
↓ 54.06%
Net Profit Margin
-203.51%
↑ 2981.19%
FY19Y/Y Change
Revenue
16.7M
↓ 3.57%
Net Income
-89.8M
↑ 154.46%
Net Profit Margin
-537.01%
↓ 333.5%
FY20Y/Y Change
Revenue
32.2M
↑ 92.3%
Net Income
-77.9M
↓ 13.21%
Net Profit Margin
-242.38%
↑ 294.63%
FY21Y/Y Change
Revenue
7.5M
↓ 76.81%
Net Income
-98.8M
↑ 26.78%
Net Profit Margin
-1.3K%
↓ 1082.87%
FY22Y/Y Change
Revenue
10.2M
↑ 36.95%
Net Income
-91.3M
↓ 7.55%
Net Profit Margin
-894.59%
↑ 430.66%
FY23Y/Y Change
Revenue
7.5M
↓ 26.54%
Net Income
-81.9M
↓ 10.35%
Net Profit Margin
-1.1K%
↓ 197.12%
Q2 FY22Q/Q Change
Revenue
2.2M
↑ 10.59%
Net Income
-21.5M
↑ 0.72%
Net Profit Margin
-964.7%
↑ 94.57%
Q3 FY22Q/Q Change
Revenue
1.4M
↓ 35.12%
Net Income
-16.9M
↓ 21.31%
Net Profit Margin
-1.2K%
↓ 205.36%
Q4 FY22Q/Q Change
Revenue
2.0M
↑ 37.21%
Net Income
-24.5M
↑ 45.02%
Net Profit Margin
-1.2K%
↓ 66.61%
Q1 FY23Q/Q Change
Revenue
1.9M
↓ 2.07%
Net Income
-18.6M
↓ 24.04%
Net Profit Margin
-959.26%
↑ 277.41%
Q2 FY23Q/Q Change
Revenue
2.1M
↑ 10.31%
Net Income
-21.9M
↑ 17.84%
Net Profit Margin
-1.0K%
↓ 65.47%
Q4 FY23Q/Q Change
Revenue
1.7M
↓ 20.8%
Net Income
-16.3M
↓ 25.77%
Net Profit Margin
-960.42%
↑ 64.31%
FY18Y/Y Change
Total Assets
692.4M
↑ 5.61%
Total Liabilities
146.4M
↑ 5.41%
FY19Y/Y Change
Total Assets
652.1M
↓ 5.82%
Total Liabilities
171.1M
↑ 16.82%
FY20Y/Y Change
Total Assets
733.6M
↑ 12.5%
Total Liabilities
184.3M
↑ 7.72%
FY21Y/Y Change
Total Assets
744.7M
↑ 1.52%
Total Liabilities
163.3M
↓ 11.37%
FY22Y/Y Change
Total Assets
662.1M
↓ 11.09%
Total Liabilities
165.1M
↑ 1.09%
FY23Y/Y Change
Total Assets
669.4M
↑ 1.1%
Total Liabilities
167.6M
↑ 1.5%
Q2 FY22Q/Q Change
Total Assets
662.1M
↓ 2.87%
Total Liabilities
165.1M
↑ 0.33%
Q3 FY22Q/Q Change
Total Assets
684.5M
↑ 3.38%
Total Liabilities
161.7M
↓ 2.06%
Q4 FY22Q/Q Change
Total Assets
668.1M
↓ 2.4%
Total Liabilities
168.1M
↑ 3.94%
Q1 FY23Q/Q Change
Total Assets
650.4M
↓ 2.64%
Total Liabilities
168.3M
↑ 0.13%
Q2 FY23Q/Q Change
Total Assets
669.4M
↑ 2.92%
Total Liabilities
167.6M
↓ 0.41%
Q4 FY23Q/Q Change
Total Assets
670.3M
↑ 0.13%
Total Liabilities
161.6M
↓ 3.59%
FY18Y/Y Change
Operating Cash Flow
-75.0M
↓ 21.43%
Investing Cash Flow
-1.2M
↓ 911.97%
Financing Cash Flow
68.6M
↑ 14.35%
FY19Y/Y Change
Operating Cash Flow
-57.8M
↓ 22.96%
Investing Cash Flow
-1000.0K
↓ 13.27%
Financing Cash Flow
71.6M
↑ 4.37%
FY20Y/Y Change
Operating Cash Flow
-56.4M
↓ 2.47%
Investing Cash Flow
-3.3M
↑ 227.3%
Financing Cash Flow
137.0M
↑ 91.38%
FY21Y/Y Change
Operating Cash Flow
-106.7M
↑ 89.27%
Investing Cash Flow
-1.6M
↓ 49.68%
Financing Cash Flow
114.5M
↓ 16.48%
FY22Y/Y Change
Operating Cash Flow
-65.8M
↓ 38.34%
Investing Cash Flow
-232.0K
↓ 85.91%
Financing Cash Flow
-9.9M
↓ 108.62%
FY23Y/Y Change
Operating Cash Flow
-63.3M
↓ 3.82%
Investing Cash Flow
-194.0K
↓ 16.38%
Financing Cash Flow
74.5M
↓ 854.83%
Q3 FY22Q/Q Change
Operating Cash Flow
-14.3M
↑ 2.83%
Investing Cash Flow
-203.0K
↑ 331.91%
Financing Cash Flow
40.3M
↓ 1918.5%
Q4 FY22Q/Q Change
Operating Cash Flow
-16.5M
↑ 15.17%
Investing Cash Flow
-34.0K
↓ 83.25%
Financing Cash Flow
-2.0M
↓ 104.99%
Q1 FY23Q/Q Change
Operating Cash Flow
-16.3M
↓ 1.24%
Investing Cash Flow
16.0K
↓ 147.06%
Financing Cash Flow
-2.5M
↑ 26.29%
Q2 FY23Q/Q Change
Operating Cash Flow
-16.3M
↑ 0.17%
Investing Cash Flow
16.0K
↑ 0.0%
Financing Cash Flow
38.8M
↓ 1625.27%

Technicals Summary

Sell

Neutral

Buy

Mesoblast is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mesoblast
Mesoblast
182.73%
-36.79%
1.97%
-61.7%
-43.56%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mesoblast
Mesoblast
0.12
NA
0.0
-0.72
-0.14
-0.06
NA
0.5
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mesoblast
Mesoblast
Buy
$677.5M
-43.56%
0.12
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • Penbrook Management LLC

    0.14%

  • Susquehanna International Group, LLP

    0.05%

  • Morgan Stanley - Brokerage Accounts

    0.04%

  • Group One Trading, LP

    0.03%

  • JANE STREET GROUP, LLC

    0.03%

  • Bank of America Corp

    0.02%

Company Information

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (mlcs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. our ‘off-the-shelf’ products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. our licensee in japan has launched its mlc-based product for acute graft versus host disease in children and adults in japan. it is the first allogeneic cell-based product in japan to be fully approved in japan. we believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the united states. our lead product candidates under investigation are: • mpc-150-im for chronic heart failure • mpc-06-id for chronic low back pain due to disc degeneration • msc-100-iv for acute graf

Organization
Mesoblast
Employees
83
CEO
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Industry
Health Technology

Discover More

FAQs